Alexandra S. Zimmer, MD, discusses the safety of the combination of the T-DM1 ado-trastuzumab emtansine and temozolomide, for the prevention of further brain metastases in patients with HER2-positive breast cancer with brain metastases.
Alexandra Higgins, MD, discusses when to use ado-trastuzumab emtansine in patients with HER2-positive breast cancer, and how to address particular adverse events that patients may develop while on treatment.
Fam-trastuzumab deruxtecan-nxki led to prolonged progression-free survival and higher responses compared with ado-trastuzumab emtansine as second-line therapy in patients with HER2-positive metastatic breast cancer.
Data from a pooled analysis confirm that patients who self-identify as Black or Hispanic can safely benefit from treatment with palbociclib plus endocrine therapy for hormone receptor–positive, HER2-negative advanced breast cancer.
A non-chemotherapy–based targeted regimen comprised of tucatinib, palbociclib, and letrozole was found to prolong central nervous system (CNS) progression-free survival (PFS) in patients with hormone receptor–positive, HER2-positive breast cancer.